|
|
Vaccine Detail
|
LMP2A-loaded conventional DC vaccine |
| Vaccine Information |
- Vaccine Name: LMP2A-loaded conventional DC vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: Epstein Barr Virus (EBV)-derived tumor antigen and Latent Membrane Protein-2 (LMP2) (NCT02115126)
- Immunization Route: Intravenous injection (i.v.)
- Description: Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines are administered alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. It may induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+ lymphoma in the setting of autologous stem cell transplant. (NCT02115126)
|
| Host Response |
|
|
| References |
NCT02115126: Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant [https://clinicaltrials.gov/study/NCT02115126]
|
|
